Galectin Therapeutics (GALT) Receiving Positive News Coverage, Report Shows

Media headlines about Galectin Therapeutics (NASDAQ:GALT) have trended positive on Saturday, according to Alpha One. Alpha One, a division of Accern, rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galectin Therapeutics earned a news impact score of 0.27 on Alpha One’s scale. Alpha One also assigned media headlines about the company an impact score of 42 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news stories that may have effected Alpha One Sentiment Analysis’s scoring:

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Shares of Galectin Therapeutics (NASDAQ GALT) traded down 5.62% during mid-day trading on Friday, reaching $2.35. 299,689 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $2.59 and its 200-day moving average price is $1.87. The stock’s market cap is $81.47 million. Galectin Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Monday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Equities research analysts forecast that Galectin Therapeutics will post ($0.50) earnings per share for the current year.

A number of research firms recently weighed in on GALT. Zacks Investment Research raised shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Tuesday. FBR & Co reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Galectin Therapeutics in a research report on Monday, April 3rd. Finally, HC Wainwright raised shares of Galectin Therapeutics from a “neutral” rating to a “buy” rating and set a $3.50 price objective on the stock in a research report on Thursday, March 30th.

TRADEMARK VIOLATION WARNING: “Galectin Therapeutics (GALT) Receiving Positive News Coverage, Report Shows” was originally published by WKRB News and is the property of of WKRB News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.wkrb13.com/markets/2230999/galectin-therapeutics-galt-receiving-positive-news-coverage-report-shows.html.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230999/galectin-therapeutics-galt-receiving-positive-news-coverage-report-shows.html

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.